| Name | BLU-945 |
|---|
| Description | receptor (EGFR). EGFR is a member of the erbB receptor family, which includes transmembrane protein tyrosine kinase receptors. BLU-945 effectively inhibits EGFR with L858R and/or exon 19 deletion mutation, T790M mutation, and C797S mutation. BLU-945 facilitates efficacious dosing and reduces EGFR-mediated on-target toxicities. S BLU-945 has the potential for the research of cancer disease (extracted from patent WO2021133809A1, compound 112)[1]. |
|---|---|
| Related Catalog | |
| References |
[1]. John Emmerson Campbell, et al. Inhibitors of mutant forms of egfr. Patent WO2021133809A1. |
| Molecular Formula | C28H37FN6O3S |
|---|---|
| Molecular Weight | 556.70 |